The advent of therapeutic approaches for Duchenne muscular dystrophy (DMD) has highlighted the need to identify reliable outcome measures for young boys with DMD. The aim of this study was to develop a revised version of the North Star Ambulatory Assessment (NSAA) suitable for boys between the age of 3 and 5 years by identifying age appropriate items and revising the scoring system accordingly. Using the scale in 171 controls between the age of 2.9 and 4.8 years, we identified items that were appropriate at different age points. An item was defined as age appropriate if it was completed, achieving a full score, by at least 85% of the typically developing boys at that age. At 3 years (+/- 3months) there were only 8 items that were age approp...
Objective: The aim of the study was to assess different outcome measures in a cohort of ambulant boy...
Objective: With the emergence of experimental therapies for Duchenne muscular dystrophy (DMD), it is...
Objective: With the emergence of experimental therapies for Duchenne muscular dystrophy (DMD), it is...
The advent of therapeutic approaches for Duchenne muscular dystrophy (DMD) has highlighted the need ...
The advent of therapeutic approaches for Duchenne muscular dystrophy (DMD) has highlighted the need ...
The advent of therapeutic approaches for Duchenne muscular dystrophy (DMD) has highlighted the need ...
The advent of therapeutic approaches for Duchenne muscular dystrophy (DMD) has highlighted the need ...
The aim of this study was to establish the suitability of the North Star Ambulatory Assessment for u...
The aim of this study was to establish the suitability of the North Star Ambulatory Assessment for u...
The aim of this study was to establish the suitability of the North Star Ambulatory Assessment for u...
The aim of this study was to establish the suitability of the North Star Ambulatory Assessment for u...
The advent of therapeutic approaches for Duchenne muscular dystrophy (DMD) has highlighted the need ...
The North Star Ambulatory Assessment is a functional scale specifically designed for ambulant boys a...
The aim of this prospective multicentric study was to document disease progression in young boys aff...
Functional variability among boys with Duchenne muscular dystrophy (DMD) is well recognised and comp...
Objective: The aim of the study was to assess different outcome measures in a cohort of ambulant boy...
Objective: With the emergence of experimental therapies for Duchenne muscular dystrophy (DMD), it is...
Objective: With the emergence of experimental therapies for Duchenne muscular dystrophy (DMD), it is...
The advent of therapeutic approaches for Duchenne muscular dystrophy (DMD) has highlighted the need ...
The advent of therapeutic approaches for Duchenne muscular dystrophy (DMD) has highlighted the need ...
The advent of therapeutic approaches for Duchenne muscular dystrophy (DMD) has highlighted the need ...
The advent of therapeutic approaches for Duchenne muscular dystrophy (DMD) has highlighted the need ...
The aim of this study was to establish the suitability of the North Star Ambulatory Assessment for u...
The aim of this study was to establish the suitability of the North Star Ambulatory Assessment for u...
The aim of this study was to establish the suitability of the North Star Ambulatory Assessment for u...
The aim of this study was to establish the suitability of the North Star Ambulatory Assessment for u...
The advent of therapeutic approaches for Duchenne muscular dystrophy (DMD) has highlighted the need ...
The North Star Ambulatory Assessment is a functional scale specifically designed for ambulant boys a...
The aim of this prospective multicentric study was to document disease progression in young boys aff...
Functional variability among boys with Duchenne muscular dystrophy (DMD) is well recognised and comp...
Objective: The aim of the study was to assess different outcome measures in a cohort of ambulant boy...
Objective: With the emergence of experimental therapies for Duchenne muscular dystrophy (DMD), it is...
Objective: With the emergence of experimental therapies for Duchenne muscular dystrophy (DMD), it is...